Literature DB >> 2873280

Psoriasis and alpha-interferon.

J R Quesada, J U Gutterman.   

Abstract

Two patients with metastatic renal carcinoma who were treated with recombinant-DNA-derived alpha-interferon (rIFN alpha) had exacerbation of concomitant psoriasis, and another patient experienced onset of psoriasis during treatment with rIFN alpha. This suggests that interferons may participate in the pathophysiology of psoriasis.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2873280     DOI： 10.1016/s0140-6736(86)91502-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  16 in total

Review 1.  Tolerability of treatments for viral hepatitis.

Authors:  A Gervais; N Boyer; P Marcellin
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases.

Authors:  M Afshar; A D Martinez; R L Gallo; T R Hata
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-06-01       Impact factor: 6.166

3.  Subacute thyroiditis during interferon-alpha therapy for chronic hepatitis C.

Authors:  P Falaschi; A Martocchia; R D'Urso; A Proietti
Journal:  J Endocrinol Invest       Date:  1997-01       Impact factor: 4.256

4.  A case of arthropathy and hypothyroidism during recombinant alpha-interferon therapy.

Authors:  S Maccari; C Bassi; A G Giovannini; A C Plancher
Journal:  Clin Rheumatol       Date:  1991-12       Impact factor: 2.980

Review 5.  Risks and benefits of interferon-alpha in the treatment of hepatitis.

Authors:  M Pardo; E Marriott; M C Moliner; J A Quiroga; V Carreño
Journal:  Drug Saf       Date:  1995-11       Impact factor: 5.606

Review 6.  Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options.

Authors:  Gil Yosipovitch; Mark B Y Tang
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 7.  [Interferon therapy and autoimmunity].

Authors:  J Fritzsch; J Krug; H J Heberling
Journal:  Med Klin (Munich)       Date:  1997-05-15

8.  Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.

Authors:  I Kötter; M Zierhut; A K Eckstein; R Vonthein; T Ness; I Günaydin; B Grimbacher; S Blaschke; W Meyer-Riemann; H H Peter; N Stübiger
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

Review 9.  Cytokine therapeutics: lessons from interferon alpha.

Authors:  J U Gutterman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

Review 10.  A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin.

Authors:  Nisha Mistry; Jonathan Shapero; Richard I Crawford
Journal:  Can J Gastroenterol       Date:  2009-10       Impact factor: 3.522
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.